Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate

Arteriosclerosis Obliterans Clinical Trial

Official title:
Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate on Symptom Improvement in Patients With Peripheral Arterial Disease

Status Completed

Clinical Trial Summary

The study will evaluate the effect of Anpl-one SR Tablet on the improvement of symptoms in daily care environments using PAQ.

Clinical Trial Description

The purpose of this study is to evaluate the effect of Anple-one SR Tablet on the improvement of symptoms in daily care environments within the scope of 300 milligrams of Anpl-one SR Tablet (sarpogrelate hydrochloride agent) using PAQ. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05083299
Study type	Observational
Source	Daewoong Pharmaceutical Co. LTD.
Contact
Status	Completed
Phase
Start date	January 28, 2020
Completion date	January 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00823849` - Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker	Phase 4
Recruiting	`NCT00912756` - Sufficient Treatment of Peripheral Intervention by Cilostazol	Phase 4
Completed	`NCT00712946` - Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages	N/A
Enrolling by invitation	`NCT02864654` - Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia	Phase 1/Phase 2
Active, not recruiting	`NCT02431234` - Arterial Calcification in the Diabetes
Completed	`NCT01518205` - HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)	N/A
Recruiting	`NCT02877173` - A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans	Phase 2
Recruiting	`NCT00145262` - TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation	Phase 2